NCT03331666View on ClinicalTrials.gov

Impact of LDL-cholesterol Lowering on Platelet Activation

PHASE4TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

November 16, 2018

Primary Completion Date

February 4, 2020

Study Completion Date

February 4, 2020

Conditions

Familial Hypercholesterolemia

Interventions

DRUG

Evolocumab

140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia

Trial Locations (1)

10032

Columbia University Medical Center, New York

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

Columbia University

OTHER